Stock News

BofI Holding, Inc. (BOFI) Reaches $32.46 52-Week High; 4 Bullish Analysts Covering Agenus Inc. (AGEN)

Among 5 analysts covering Agenus (NASDAQ:AGEN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Agenus had 10 analyst reports since July 27, 2015 according to SRatingsIntel. The rating was initiated by Jefferies on Wednesday, December 16 with “Buy”. The stock of Agenus Inc. (NASDAQ:AGEN) earned “Buy” rating by Maxim Group on Thursday, October 27. The rating was upgraded by Maxim Group on Friday, March 11 to “Buy”. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, March 9. The rating was maintained by Jefferies with “Buy” on Thursday, August 3. On Monday, June 26 the stock rating was maintained by Jefferies with “Buy”. MLV maintained Agenus Inc. (NASDAQ:AGEN) rating on Monday, July 27. MLV has “Buy” rating and $11 target. On Tuesday, October 27 the stock rating was downgraded by Maxim Group to “Hold”. The stock has “Neutral” rating by H.C. Wainwright on Friday, October 28. On Friday, July 29 the stock rating was maintained by Jefferies with “Buy”. See Agenus Inc. (NASDAQ:AGEN) latest ratings:

03/08/2017 Broker: Jefferies Rating: Buy New Target: $7.0000 Maintain

The stock of BofI Holding, Inc. (NASDAQ:BOFI) hit a new 52-week high and has $34.08 target or 5.00% above today’s $32.46 share price. The 7 months bullish chart indicates low risk for the $2.07 billion company. The 1-year high was reported on Jan, 16 by Barchart.com. If the $34.08 price target is reached, the company will be worth $103.30 million more. The stock increased 2.82% or $0.89 during the last trading session, reaching $32.46. About 542,209 shares traded. BofI Holding, Inc. (NASDAQ:BOFI) has risen 28.16% since January 16, 2017 and is uptrending. It has outperformed by 11.46% the S&P500.

BofI Holding, Inc. operates as the holding firm for BofI Federal Bank that provides consumer and business banking products in the United States. The company has market cap of $2.07 billion. The firm offers deposits products, including consumer and business checking, demand, savings, and time deposit accounts. It has a 15.31 P/E ratio. It also provides single family and multifamily mortgage secured lending products; commercial real estate secured and commercial lending products; specialty finance factoring products; and consumer lending products consisting of prime loans to purchase new and used automobiles and recreational vehicles, as well as deposit-related overdraft lines of credit.

Among 7 analysts covering Bofl Holding Inc (NASDAQ:BOFI), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Bofl Holding Inc had 17 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was maintained by FBR Capital on Thursday, October 26 with “Buy”. The rating was maintained by Keefe Bruyette & Woods on Thursday, December 21 with “Hold”. Wood downgraded the stock to “Market Perform” rating in Monday, October 9 report. The stock of BofI Holding, Inc. (NASDAQ:BOFI) earned “Neutral” rating by DA Davidson on Thursday, August 6. The stock has “Hold” rating by Keefe Bruyette & Woods on Monday, October 9. The firm has “Outperform” rating by FBR Capital given on Monday, November 23. The rating was upgraded by Raymond James on Friday, September 4 to “Strong Buy”. The firm has “Buy” rating given on Tuesday, January 9 by Sandler O’Neill. Sandler O’Neill upgraded BofI Holding, Inc. (NASDAQ:BOFI) on Thursday, October 15 to “Buy” rating. FBR Capital maintained the shares of BOFI in report on Friday, July 31 with “Outperform” rating.

Investors sentiment decreased to 0.98 in Q3 2017. Its down 0.10, from 1.08 in 2017Q2. It worsened, as 12 investors sold BofI Holding, Inc. shares while 72 reduced holdings. 34 funds opened positions while 48 raised stakes. 51.41 million shares or 4.88% less from 54.04 million shares in 2017Q2 were reported. Ohio-based Fifth Third Bancorporation has invested 0% in BofI Holding, Inc. (NASDAQ:BOFI). Swiss Bancshares invested 0% in BofI Holding, Inc. (NASDAQ:BOFI). Private Asset Management reported 1,215 shares or 0.2% of all its holdings. Ubs Asset Management Americas Inc reported 34,256 shares or 0% of all its holdings. Cornerstone Cap Mgmt Ltd Liability holds 0.01% in BofI Holding, Inc. (NASDAQ:BOFI) or 33,800 shares. Morgan Stanley invested in 321,870 shares or 0% of the stock. State Treasurer State Of Michigan holds 0.22% of its portfolio in BofI Holding, Inc. (NASDAQ:BOFI) for 961,487 shares. Fred Alger has 1.17 million shares. Pembroke Ltd accumulated 1.22M shares. Amalgamated Bancorp invested in 8,123 shares. Tci Wealth stated it has 107 shares or 0% of all its holdings. Moreover, Cwm Llc has 0.01% invested in BofI Holding, Inc. (NASDAQ:BOFI) for 5,800 shares. Great West Life Assurance Co Can stated it has 75,450 shares. Pacific Ridge Cap Prtnrs Ltd Co invested 0.53% in BofI Holding, Inc. (NASDAQ:BOFI). Metropolitan Life Insur Co New York owns 40,820 shares.

Analysts await BofI Holding, Inc. (NASDAQ:BOFI) to report earnings on January, 29. They expect $0.52 EPS, up 4.00% or $0.02 from last year’s $0.5 per share. BOFI’s profit will be $33.10M for 15.61 P/E if the $0.52 EPS becomes a reality. After $0.50 actual EPS reported by BofI Holding, Inc. for the previous quarter, Wall Street now forecasts 4.00% EPS growth.

The stock decreased 2.33% or $0.09 during the last trading session, reaching $3.78. About 956,094 shares traded. Agenus Inc. (NASDAQ:AGEN) has declined 2.26% since January 16, 2017 and is downtrending. It has underperformed by 18.96% the S&P500.

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodyÂ’s immune system for patients suffering with cancer. The company has market cap of $378.69 million. The firm offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It currently has negative earnings. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3.

Investors sentiment increased to 1.34 in 2017 Q3. Its up 0.29, from 1.05 in 2017Q2. It increased, as 14 investors sold Agenus Inc. shares while 18 reduced holdings. 15 funds opened positions while 28 raised stakes. 36.96 million shares or 3.93% less from 38.48 million shares in 2017Q2 were reported. Crestwood Advisors Group Lc invested in 0.01% or 32,928 shares. Goldman Sachs Group Inc invested in 362,987 shares. 803 are owned by Peddock Capital Advisors Limited Company. Morgan Stanley stated it has 0% in Agenus Inc. (NASDAQ:AGEN). Highbridge Capital Ltd Liability Com invested in 56,642 shares. 35,000 are held by Modera Wealth Mngmt Limited Liability Company. Venbio Select Advisor Limited Liability Company holds 2.46 million shares or 0.84% of its portfolio. Citigroup reported 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN). Hudson Bay Cap Limited Partnership invested 0.03% of its portfolio in Agenus Inc. (NASDAQ:AGEN). Oracle Mngmt reported 1.60M shares. Sei stated it has 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN). Ny State Common Retirement Fund holds 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN) for 69,600 shares. Rhumbline Advisers accumulated 86,868 shares or 0% of the stock. Royal Bancorporation Of Canada stated it has 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN). Bruce & has 155,677 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *